Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment

Free Radical Biology and Medicine

Volumn 52, Issue 11-12, 2012, Pages 2292-2301

  Barone, Eugenio ^a,b   Di Domenico, Fabio ^a,c   Sultana, Rukhsana ^a   Coccia, Raffaella ^c   Mancuso, Cesare ^b   Perluigi, Marzia ^c   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer disease; Free radicals; Heme oxygenase; Mild cognitive impairment; Oxidative stress

Indexed keywords

BETA ACTIN; HEME OXYGENASE 1; HEME OXYGENASE 2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SERINE; THREONINE; TYROSINE;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CELLULAR STRESS RESPONSE; CEREBELLUM; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NEUROPROTECTION; NITROSATIVE STRESS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; UPREGULATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN; FEMALE; HEME OXYGENASE-1; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84861601576     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.03.020     Document Type: Article

References (70)

1. W.R. Markesbery Oxidative stress hypothesis in Alzheimers disease Free Radical Biol. Med. 23 1997 134 147
2. M.A. Smith, P.L. Richey, S. Taneda, R.K. Kutty, L.M. Sayre, V.M. Monnier, and G. Perry Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimers disease Ann. N. Y. Acad. Sci. 738 1994 447 454
3. S.S. Mirra The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimers disease: a commentary Neurobiol. Aging 18 1997 S91 S94
4. H.W. Querfurth, and F.M. LaFerla Alzheimers disease N. Engl. J. Med. 362 2010 329 344
5. C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones Alzheimers disease Lancet 377 2011 1019 1031
6. A. Mohamed, L. Cortez, and E.P. de Chaves Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide Curr. Protein Pept. Sci. 12 2011 235 257
7. J. Drake, C.D. Link, and D.A. Butterfield Oxidative stress precedes fibrillar deposition of Alzheimers disease amyloid β-peptide (1-42) in a transgenic Caenorhabditis elegans model Neurobiol. Aging 24 2003 415 420
8. J.C. Lambert, D.M. Mann, J.M. Harris, M.C. Chartier-Harlin, A. Cumming, J. Coates, H. Lemmon, D. StClair, T. Iwatsubo, and C. Lendon The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimers disease and an increased Aβ load in brain J. Med. Genet. 38 2001 353 355
9. T. Oda, P. Wals, H.H. Osterburg, S.A. Johnson, G.M. Pasinetti, T.E. Morgan, I. Rozovsky, W.B. Stine, S.W. Snyder, and T.F. Holzman Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress Exp. Neurol. 136 1995 22 31
10. D.M. Walsh, D.M. Hartley, Y. Kusumoto, Y. Fezoui, M.M. Condron, A. Lomakin, G.B. Benedek, D.J. Selkoe, and D.B. Teplow Amyloid β-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates J. Biol. Chem. 274 1999 25945 25952
11. D.A. Butterfield, and C.M. Lauderback Lipid peroxidation and protein oxidation in Alzheimers disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress Free Radical Biol. Med. 32 2002 1050 1060
12. M.A. Smith, G. Perry, and W.A. Pryor Causes and consequences of oxidative stress in Alzheimers disease Free Radical Biol. Med. 32 2002 1049
13. D.A. Butterfield, V. Galvan, M.B. Lange, H. Tang, R.A. Sowell, P. Spilman, J. Fombonne, O. Gorostiza, J. Zhang, R. Sultana, and D.E. Bredesen In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP Free Radical Biol. Med. 48 2010 136 144
14. R.C. Petersen Mild cognitive impairment clinical trials Nat. Rev. Drug Discovery 2 2003 646 653
15. G.A. Jicha, J.E. Parisi, D.W. Dickson, K. Johnson, R. Cha, R.J. Ivnik, E.G. Tangalos, B.F. Boeve, D.S. Knopman, H. Braak, and R.C. Petersen Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia Arch. Neurol. 63 2006 674 681
16. R. Sultana, M. Perluigi, and D.A. Butterfield Oxidatively modified proteins in Alzheimers disease (AD), mild cognitive impairment and animal models of AD: role of Aβ in pathogenesis Acta Neuropathol. 118 2009 131 150
17. R.C. Petersen Clinical practice: mild cognitive impairment N. Engl. J. Med. 364 2011 2227 2234
18. V. Calabrese, C. Cornelius, C. Mancuso, E. Barone, S. Calafato, T. Bates, E. Rizzarelli, and A.T. Kostova Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases Front. Biosci. 14 2009 376 397
19. C. Mancuso, G. Scapagini, D. Curro, A.M. Giuffrida Stella, C. De Marco, D.A. Butterfield, and V. Calabrese Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders Front. Biosci. 12 2007 1107 1123
20. H.F. Poon, V. Calabrese, G. Scapagnini, and D.A. Butterfield Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress J. Gerontol. A Biol. Sci. Med. Sci. 59 2004 478 493
21. M.D. Maines The heme oxygenase system: a regulator of second messenger gases Annu. Rev. Pharmacol. Toxicol. 37 1997 517 554
22. M.D. Maines The heme oxygenase system and its functions in the brain Cell. Mol. Biol. (Noisy-le-Grand) 46 2000 573 585
23. C. Mancuso Heme oxygenase and its products in the nervous system Antioxid. Redox Signal. 6 2004 878 887
24. Butterfield, D. A.; Barone, E.; Di Domenico, F.; Cenini, G.; Sultana, R.; Murphy, M. P.; Mancuso, C.; Head, E. Atorvastatin treatment in adog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1and is associated with reduced oxidative stress in brain. Int. J. Neuropsychopharmacol. , in press Available on CJO 2011. 10.1017/S1461145711001118
25. M.D. Maines, and N. Panahian The heme oxygenase system and cellular defense mechanisms: do HO-1 and HO-2 have different functions? Adv. Exp. Med. Biol. 502 2001 249 272
26. R. Stocker Antioxidant activities of bile pigments Antioxid. Redox Signal. 6 2004 841 849
27. C. Mancuso, and E. Barone The heme oxygenase/biliverdin reductase pathway in drug research and development Curr. Drug Metab. 10 2009 579 594
28. M. Salinas, J. Wang, M. Rosa de Sagarra, D. Martin, A.I. Rojo, J. Martin-Perez, P.R. Ortiz de Montellano, and A. Cuadrado Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in vitro and in vivo FEBS Lett. 578 2004 90 94
29. J. Kapitulnik, and M.D. Maines Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin Trends Pharmacol. Sci. 30 2009 129 137
30. B.E. Dwyer, R.N. Nishimura, and S.Y. Lu Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody: response to oxidative stress Brain Res. Mol. Brain Res. 30 1995 37 47
31. J.F. Ewing, C.M. Weber, and M.D. Maines Biliverdin reductase is heat resistant and coexpressed with constitutive and heat shock forms of heme oxygenase in brain J. Neurochem. 61 1993 1015 1023
32. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, R. Coccia, P. Preziosi, M. Perluigi, C. Mancuso, and D.A. Butterfield Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimers disease and amnestic mild cognitive impairment J. Alzheimers Dis. 25 2011 623 633
33. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, C. Cini, P. Preziosi, M. Perluigi, C. Mancuso, and D.A. Butterfield Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment Biochim. Biophys. Acta 1812 2011 480 487
34. Y. Hui, D. Wang, W. Li, L. Zhang, J. Jin, N. Ma, L. Zhou, O. Nakajima, W. Zhao, and X. Gao Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation J. Alzheimers Dis. 26 2011 299 313
35. H.M. Schipper, A. Gupta, and W.A. Szarek Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD Curr. Alzheimer Res. 6 2009 424 430
36. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease Neurology 34 1984 939 944
37. G. Cenini, R. Sultana, M. Memo, and D.A. Butterfield Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease Free Radical Biol. Med. 45 2008 81 85
38. M. Salim, B.A. Brown-Kipphut, and M.D. Maines Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation J. Biol. Chem. 276 2001 10929 10934
39. N. Lerner-Marmarosh, T. Miralem, P.E. Gibbs, and M.D. Maines Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling Proc. Natl. Acad. Sci. USA 105 2008 6870 6875
40. C.C. Conrad, J.M. Talent, C.A. Malakowsky, and R.W. Gracy Post-electrophoretic identification of oxidized proteins Biol. Proced. Online 2 2000 39 45
41. H.M. Schipper, S. Cisse, and E.G. Stopa Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain Ann. Neurol. 37 1995 758 768
42. V. Calabrese, R. Sultana, G. Scapagnini, E. Guagliano, M. Sapienza, R. Bella, J. Kanski, G. Pennisi, C. Mancuso, A.M. Stella, and D.A. Butterfield Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimers disease Antioxid. Redox Signal. 8 2006 1975 1986
43. F. Di Domenico, R. Sultana, G.F. Tiu, N.N. Scheff, M. Perluigi, C. Cini, and D.A. Butterfield Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease Brain Res. 1333 2010 72 81
44. M.D. Maines Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications FASEB J. 2 1988 2557 2568
45. J.N. Keller, F.A. Schmitt, S.W. Scheff, Q. Ding, Q. Chen, D.A. Butterfield, and W.R. Markesbery Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology 64 2005 1152 1156
46. K. Hensley, N. Hall, R. Subramaniam, P. Cole, M. Harris, M. Aksenov, M. Aksenova, S.P. Gabbita, J.F. Wu, and J.M. Carney Brain regional correspondence between Alzheimers disease histopathology and biomarkers of protein oxidation J. Neurochem. 65 1995 2146 2156
47. W.R. Markesbery Neuropathologic alterations in mild cognitive impairment: a review J. Alzheimers Dis. 19 2010 221 228
48. D.R. Premkumar, M.A. Smith, P.L. Richey, R.B. Petersen, R. Castellani, R.K. Kutty, B. Wiggert, G. Perry, and R.N. Kalaria Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimers disease J. Neurochem. 65 1995 1399 1402
49. C.M. Weber, B.C. Eke, and M.D. Maines Corticosterone regulates heme oxygenase-2 and NO synthase transcription and protein expression in rat brain J. Neurochem. 63 1994 953 962
50. Z. Chen, H. Xu, S. Haimano, X. Li, and X.M. Li Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats Neurosci. Lett. 389 2005 173 177
51. V.S. Raju, W.K. McCoubrey Jr., and M.D. Maines Regulation of heme oxygenase-2 by glucocorticoids in neonatal rat brain: characterization of a functional glucocorticoid response element Biochim. Biophys. Acta 1351 1997 89 104
52. G. Rauchs, C. Harand, F. Bertran, B. Desgranges, and F. Eustache Sleep and episodic memory: a review of the literature in young healthy subjects and potential links between sleep changes and memory impairment observed during aging and Alzheimers disease Rev. Neurol. (Paris) 166 2010 873 881
53. K.N. Green, L.M. Billings, B. Roozendaal, J.L. McGaugh, and F.M. LaFerla Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimers disease J. Neurosci. 26 2006 9047 9056
54. J.K. Lei Change of serum ACTH and cortisol levels in Alzheimer disease and mild cognition impairment Zhonghua Yi Xue Za Zhi 90 2010 2894 2896
55. R.M. Sapolsky Glucocorticoid toxicity in the hippocampus: temporal aspects of neuronal vulnerability Brain Res. 359 1985 300 305
56. R.M. Sapolsky, and W.A. Pulsinelli Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications Science 229 1985 1397 1400
57. C. Catania, I. Sotiropoulos, R. Silva, C. Onofri, K.C. Breen, N. Sousa, and O.F. Almeida The amyloidogenic potential and behavioral correlates of stress Mol. Psychiatry 14 2009 95 105
58. R. Subramaniam, F. Roediger, B. Jordan, M.P. Mattson, J.N. Keller, G. Waeg, and D.A. Butterfield The lipid peroxidation product, 4-hydroxy-2-trans- nonenal, alters the conformation of cortical synaptosomal membrane proteins J. Neurochem. 69 1997 1161 1169
59. J.B. Owen, R. Sultana, C.D. Aluise, M.A. Erickson, T.O. Price, G. Bu, W.A. Banks, and D.A. Butterfield Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain Free Radical Biol. Med. 49 2010 1798 1803
60. C.M. Lauderback, J.M. Hackett, F.F. Huang, J.N. Keller, L.I. Szweda, W.R. Markesbery, and D.A. Butterfield The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimers disease brain: the role of Aβ1-42 J. Neurochem. 78 2001 413 416
61. A. Takeda, M.A. Smith, J. Avila, A. Nunomura, S.L. Siedlak, X. Zhu, G. Perry, and L.M. Sayre In Alzheimers disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification J. Neurochem. 75 2000 1234 1241
62. E. Barone, C. Mancuso, F. Di Domenico, R. Sultana, M.P. Murphy, E. Head, and D.A. Butterfield Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease J. Neurochem. 120 2011 135 146
63. S. Shibahara The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism Tohoku J. Exp. Med. 200 2003 167 186
64. S. Shibahara, M. Nakayama, T. Kitamuro, R. Udono-Fujimori, and K. Takahashi Repression of heme oxygenase-1 expression as a defense strategy in humans Exp. Biol. Med. (Maywood) 228 2003 472 473
65. S.D. Brown, and C.A. Piantadosi Recovery of energy metabolism in rat brain after carbon monoxide hypoxia J. Clin. Invest. 89 1992 666 672
66. J. Zhang, and C.A. Piantadosi Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain J. Clin. Invest. 90 1992 1193 1199
67. H.M. Schipper, L. Bernier, K. Mehindate, and D. Frankel Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore J Neurochem. 72 1999 1802 1811
68. T.I. Williams, B.C. Lynn, W.R. Markesbery, and M.A. Lovell Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimers disease Neurobiol. Aging 27 2006 1094 1099
69. M.A. Bradley, S. Xiong-Fister, W.R. Markesbery, and M.A. Lovell Elevated 4-hydroxyhexenal in Alzheimers disease (AD) progression Neurobiol. Aging 33 2012 1034 1044
70. M.A. Smith, X. Zhu, M. Tabaton, G. Liu, D.W. McKeel Jr, M.L. Cohen, X. Wang, S.L. Siedlak, B.E. Dwyer, T. Hayashi, M. Nakamura, A. Nunomura, and G. Perry Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment J. Alzheimers Dis. 19 2010 363 372